Acasia Technology, Inc.

AI-generated fair value estimate for this company.

Method: Net asset value / liquidation approach (no DCF possible: no revenue or operating cash flow): per the Sept 30, 2025 10-Q, total assets of $19,157 (100% cash) minus total liabilities of $53,296 ($52,496 related-party loan plus $800 payables) equal a stockholders' deficit of $(34,139); NAV per share floored at $0.00 (versus the small negative implied figure) against 42,959,574 shares outstanding.

Reasoning: ACAT (formerly NP Life Sciences Health Industry Group, rebranded 'Acasia Technology' in May 2025 — the current, unrelated company, not the old Arctic Cat) is a shell with zero revenue while it searches for a reverse-merger target, so a DCF cannot be built; liquidation NAV is the only grounded method and implies negligible fundamental value, with the ~$0.13 quoted price reflecting speculative merger-shell optionality rather than assets.